Article Search

955 individuals were screened for eligibility, 747 of whom were randomly assigned to belzutifan–lenvatinib (n=371) or cabozantinib (n=376). 565 (76%)

Adjuvant therapy with pazopanib after metastesectomy for met-ccRCC did not show a meaningful benefit. It seems that the current standard is for adjuvant pembro after metastesectomy within a year of nephrectomy.

Atezo and cabo is a NO.